US stocks movement: ImmunityBio surged on October 27, driven by Kramer’s optimism and biotech mergers and acquisitions

ImmunityBio October 27 Surge Interpretation

Keywords: Cramer optimistic, biopharmaceutical mergers and acquisitions

1. On October 26, during the "Lightning Round" segment of CNBC's "Mad Money," Jim Cramer called ImmunityBio a "very good speculative pick" and mentioned active mergers and acquisitions in the biopharmaceutical sector.

2. On October 21, the company announced database lock for the QUILT-2.005 trial, enrolling 366 patients; an interim analysis required by the FDA showed that the duration of complete remission in the ANKTIVA plus BCG group was significantly longer. The company expects to announce topline results in November 2026 and plans to submit a supplemental biologics license application in the fourth quarter.

3. On October 14, the FDA expanded the indication for ANKTIVA combined with BCG for bladder cancer to include patients with only papillary tumors, thus covering all BCG-unresponsive non-muscle invasive bladder cancer patients.

(Disclaimer: This content is generated by AI technology summarizing publicly available information for reference only and does not constitute investment advice.)